A number of pre-clinical studies now demonstrate that PARG inhibitors show promise as anti-cancer therapeutics, however, our understanding of the consequences of PARG inhibition need to further be refined and the identification of novel contexts in which PARG has promise as a target for inhibition need to be determined. Here, PARG is linked to cancer.